Figure 7

CLL cells are not sensitive to inhibition of KIT, PDGFR and FLT3 but are sensitive to inhibition of RAF and VEGFR. (A) Summary of sorafenib, KG1, KG5 and vatalanib targets. (B) CLL B cells purified from frozen PBMCs were cultured in the absence of support cells and exposed to sorafenib, KG1 or KG5 compound (all at 10 µmol/L) or DMSO, added once on d 0. After 48 h, CLL cells were analyzed for viability as in Figure 2. Data shown are means ± SD from six different CLL samples. (C, D) CLL cells purified from frozen PBMCs were cocultured in the presence of MSCs with a single dose of sorafenib, KG1, KG5 (all at 10 µmol/L) or DMSO added once at the beginning of the culture. CLL cell viability was determined as above. (C) Results are represented relative to DMSO as means ± SD from three different CLL samples. (D) The 48-h time point of the time course is presented as a bar graph, along with the statistical analysis comparing the inhibitors with one another using a paired Student t test. (E, F) Purified CLL cells were cocultured in the presence of MSCs with a single dose of sorafenib, vatalanib (both at 10 µmol/L) or DMSO added once at d 0. Viability was measured as above. (E) Results are represented relative to DMSO, as means ± SD from three different CLL samples. (F) The 48-h time point of the time course is presented as a bar graph, along with the statistical analysis comparing the inhibitors with one another using a paired Student t test. *P < 0.05; **P < 0.01; ***p < 0.001.